Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176239 · ClinicalTrials.gov registry record
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
A clinical trial of Primary Immunodeficiency Disease (PIDD), sponsored by BriovaRx Infusion Services.
- Completed
- Registry status
- 20
- Enrollment target
- 4
- Study locations
NCT02176239 is a study of Primary Immunodeficiency Disease (PIDD) that has completed, run by BriovaRx Infusion Services. The registered enrollment target is 20 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02176239, a study of Primary Immunodeficiency Disease (PIDD), has completed, sponsored by BriovaRx Infusion Services.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments using CareExchange in the home setting.
Conditions Studied
Study Locations (4)
California
- Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare) - Newport Beach
Colorado
- IMMUNEOe International Research Centers - Centennial
Georgia
- Atlanta ENT - Atlanta
Kansas
- AxelaCare Health Solutions, LLC - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176239
The ClinicalTrials.gov registry entry for NCT02176239 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BriovaRx Infusion Services, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immunodeficiency Disease (PIDD) appearing as the primary indexed condition, and to 0 interventions.
NCT02176239 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT02176239 about?
NCT02176239 is a clinical study titled "Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting". The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments us...
What is the current status of trial NCT02176239?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-06. Estimated completion is 2019-08.
What conditions does trial NCT02176239 study?
This clinical trial studies the following conditions: Primary Immunodeficiency Disease (PIDD).
Who is sponsoring clinical trial NCT02176239?
This trial is sponsored by BriovaRx Infusion Services, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02176239 being conducted?
This trial has 4 study locations across California, Colorado, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.